TP53 and neoplasm: Overall, a Mif depletion in established AOM/DSS-induced tumors strongly affected tumor cell proliferation in both TP53-engineered models (Fig. 5E, F), explaining the smaller tumor areas observed in TAM-treated MifΔ/Δ cohorts (Figs. 2D and 4D).